"For a list of all the ways technology has failed to improve the quality of life, please press three."
|Application No.||Application Title||Issue Date|
|20130281387||Chemosensory Receptor Ligand-Based Therapies|
Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory receptor ligand. Also provided herein...
|20130231296||NEW DRUG COMBINATIONS FOR THE TREATMENT OF MALARIA|
The present invention relates to pharmaceutical preparations/compositions comprising 3-N-formyl hydroxy amino propyl phosphonic acid derivatives or 3-N-acetyl hydroxy amino propyl phosphonic acid derivatives as active ingredients in combination with Piperaquine....
|20130225529||PHOSPHO-ESTER DERIVATIVES AND USES THEREOF|
Phospho-ester compounds and pharmaceutical compositions thereof administered by the respiratory and other routes for the prevention and/or treatment of lung and brain cancer and precancerous conditions thereof, for the treatment of pain, for the treatment of skin disord...
|20130210744||TARGETING AGENT FOR CANCER CELL OR CANCER-ASSOCIATED FIBROBLAST|
Disclosed are a novel therapeutic agent and a novel treatment method for cancer. Specifically disclosed are: a targeting agent for a cell selected from the group consisting of a cancer cell and a cancer-associated fibroblast, which comprises a retinoid and/or derivative...
|20130178446||METHOD FOR DECREASING SEBUM PRODUCTION|
The present invention is directed to the topical application of the malonamide ACAT inhibitors described by Formula I. Other aspects of the invention are directed to topical formulations of these diamides, their use to treat sebaceous gland disorders and their use to al...
|20130137571||Crystalline Modification of Fipronil|
The present invention relates to a novel crystalline modification of fipronil, to a process for the preparation of the same, to pesticidal and parasiticidal mixtures and compositions comprising said crystalline modification and to their use for combating pests and paras...
|20130102570||PROPHYLACTIC AGENT OR THERAPEUTIC AGENT FOR DIABETES OR OBESITY|
A medicament having an excellent CaSR agonist action which enables the prevention or treatment of diabetes or obesity is provided by a composition comprising the compound represented by general formula (I) as defined, or a salt thereof....
|20130096092||THIOETHER PRODRUG COMPOSITIONS AS ANTI-HIV AND ANTI-RETROVIRAL AGENTS|
Disclosed are inhibitors of retroviral growth of formula (I), that are useful in treatment of retroviral infections such as HIV. Also disclosed are a composition comprising a pharmaceutically acceptable carrier and at least one compound or salt of the invention, a metho...
This document discloses molecules having the following formula (“Formula I”):
|20130065861||COMPOUNDS (CYSTEIN BASED LIPOPEPTIDES) AND COMPOSITIONS AS TLR2 AGONISTS USED FOR TREATING INFECTIONS, INFLAMMATIONS, RESPIRATORY DISEASES ETC.|
The invention provides a novel class of compounds viz. generally lipopeptides like Pam3CSK4, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with ...
|20130065850||TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS|
Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral repl...
|20130017249||COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY|
Here described are compounds consisting of the structure
wherein the targeting molecule is a reti...
The invention describes anti-cancer therapies comprising using dual Aurora kinase/MEK inhibitors as described herein....
|20120322654||SYNERGISTIC FUNGICIDAL MIXTURES|
The present invention relates to a mixture, comprising the succinate dehydrogenase inhibitor boscalid and at least one insecticidally active compound II selected from groups A) to D) as defined in the description in a synergistically effective amount, and to composition...
|20120283201||9-SUBSTITUTED MINOCYCLINE COMPOUNDS|
The present invention pertains, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applicat...
|20120283216||FUNGICIDAL 2-(BICYCLIC ARYLOXY)CARBOXAMIDES|
Disclosed are compounds of Formula 1, N-oxides, and salts thereof,
|20120270843||PESTICIDE COMPOSITION COMPRISING PROPAMOCARB-FOSETYLATE AND AN INSECTICIDALLY ACTIVE SUBSTANCE|
The present invention relates to a pesticide composition intended for protecting plants, crops or seeds against phyto-pathogenic fungi or damaging insects, and the corresponding methods of treatment using the said composition. More precisely, the subject of the present ...
|20120252764||COMPOSITIONS AND METHODS FOR PROTECTING CELLS FROM TOXIC EXPOSURES|
The present invention provides compositions and methods for protecting cells and tissues from damage associated with therapeutic treatments of cancers and other diseases and conditions where reactive oxygen species are produced. The present invention also provides compo...
|20120238521||Compositions and Methods for the Treatment of Musculoskeletal Related Diseases and Disorders Using Metal Ion-Citrate Analog Complexes|
The invention is directed to a composition and associated method for the treatment of musculoskeletal related disorders and diseases. In particular, the present invention provides a class of citrate compounds that can be used to for the treatment of diseases/disorders c...
|20120214769||Novel Antagonists of the Glucagon Receptor|
The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions co...
|20120208784||SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES|
The present invention relates to a series of substituted 3-aminopropane phosphinic acid derivatives of formula I:
wherein R, R1, P1, P2 and P3 are as defined herein...
|20120202777||C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents|
The present invention is directed to a new class of hydroxamic acid derivatives of Formula I,
wherein the variables G, T, D, L, A, X, R1 and R2 are as described hereinabove, and their us...
|20120196835||ENZYME INHIBITING COMPOUNDS AND METHODS|
The invention provides compounds, compositions, and methods for studying the Rohmer pathway and for treating bacterial infections or parasitic infections. The parasitic infection can be a protozoan infection, such as malaria. The compounds and compositions can also be u...
|20120189566||EXTERNAL PREPARATION CONTAINING PANTETHINE PHOSPHATE ESTER|
A pantethine phosphate ester represented by the following formula (1) or formula (2) exhibits superior tyrosinase inhibitory effect and melanin production inhibitory effect.
|20120178721||IMMUNOMODULATORY COMPOUNDS AND TREATMENT OF DISEASES RELATED TO AN OVERPRODUCTION OF INFLAMMATORY CYTOKINES|
Method of using immunomodulatory compounds for treating diseases related to an overproduction of inflammatory cytokines, including diseases selected from asthma, atopic dermatitis, allergic rhinitis, prostatitis, inflammatory bowel disease, diabetes, and rheumatoid arth...
Disclosed are compounds of Formula 1, N-oxides, and salts thereof,
|20120108549||NEUROPROTECTIVE COMPOUNDS AND THEIR USE|
Apocynin derivative compounds, active pharmaceutical ingredients, dosage forms, and methods of use thereof as neuroprotectants in the brain of mammals....
The present invention relates to compositions that may alleviate symptoms of ocular stress, as well as methods of their production, use, and storage compositions. The compositions comprise at least one ocular epithelial cell associating group and at least one hydrophili...
|20120088730||USE OF ANGIOTENSIN CONVERTING ENZYME (ACE) DOMAIN SPECIFIC INHIBITORS TO INHIBIT OR ENHANCE CYTOKINE PRODUCTION AND ALTER IMMUNE RESPONSE|
The present invention relates to the discovery that the two ACE domains can have very different effects on cytokine expression. In one embodiment, the present invention provides a method of regulating and/or treating a condition in a subject by administering a therapeut...
|20120077780||Fat Accumulation Inhibitor and Method of Use Thereof|
The present disclosure relates to a method of inhibiting a fat accumulation for a fat cell in a subject, which includes administering a fat accumulation inhibitor for a fat cell which includes a milk-derived phospholipid as an active ingredient to the subject. The prese...
|20120053151||DIMETHOATE LOW VOC FORMULATIONS|
Liquid dimethoate formulations comprising a solvent chosen among liquids comprised of a compound having a ethylenglycol-propylenglycol co-polymeric chain as well as mixtures thereof. These solvents diminish the use of VOC solvents while still providing storage stable fo...
|20120035135||Treatment of Transgenic Crops with Mixtures of Fiproles and Chloronicotinyls|
The Invention relates to methods for increasing the production potential of plants and/or controlling pests in plants with at least one transgenic modification related to yield increase as compared to a corresponding wild-type plant, comprising treating the location whe...
|20120021901||Active Compound Combinations Having Insecticidal and Acaricidal Properties|
The present invention relates to novel active compound combinations comprising, firstly, at least one known compound of the formula (I)
|20120022024||ANTI-BACTERIAL COMPOSITIONS AND METHODS INCLUDING TARGETING VIRULENCE FACTORS OF STAPHYLOCOCCUS AUREUS|
This disclosure relates to compositions and methods including for the inhibition, prevention, and/or treatment of microbial infections, including infections from such pathogens as Staphylococcus aureus. ...
|20120015909||MAO-B INHIBITORS USEFUL FOR TREATING OBESITY|
The invention provides novel compounds of formulae I and II:
that are monoamine oxidase-B inhibitors, which can be useful in treating obesity, diabetes, and/or cardiometabolic disorders (e.g., hypertension, d...
|20120003158||Biomarkers for Inflammatory Bowel Disease and Methods Using the Same|
The present invention provides various biomarkers of inflammatory bowel disease, including biomarkers for Crohn's disease and biomarkers for Ulcerative colitis. The present invention also provides various methods of using the biomarkers, including methods for diagnosis ...
|20110319363||NOVEL PHOSPHONIC ACID COMPOUNDS AS INHIBITORS OF SERINE PROTEASES|
The present invention is directed to phosphonic acid compounds useful as serine protease inhibitors, compositions thereof and methods for treating inflammatory and serine protease mediated disorders....
|20110319366||Plasma Carboxypeptidase B Inhibitors|
Compounds of the following formula (I), for example:
wherein R1, R2, R3, and R4 are described herein, are useful as inhibitors of plasma carboxypeptidase B. Pharmac...
|20110306578||USE OF ORGANOPHOSPHORUS COMPOUNDS FOR THE THERAPEUTIC AND PROPHYLACTIC TREATMENT OF INFECTIONS|
Use of organophosphorus compounds of general Formula (I)
for the therapeutic and prophylactic treatment of infections in humans and animals caused by viruses, fungi and parasites....
|20110294758||NOVEL ACTIVATORS OF GLUCOKINASE|
The present invention provides for novel compounds of Formulas I and II and pharmaceutically acceptable salts and co-crystals thereof which have glucokinsae activator activity. The present invention further provides for pharmaceutical compositions comprising the same as...